Sign up
An older woman with gray hair calmly looks at her tablet

Roche announces negative results from phase 3 Alzheimer's study

17 November 2022 3 minute read

Dr. Niels Prins, neurologist and director of the Brain Research Center

On Monday, November 14, pharmaceutical company Roche announced that the Alzheimer's drug gantenerumab did not lead to a delay in clinical deterioration in two large phase 3 studies conducted in patients in the early stages of Alzheimer's disease. Participants from Brain Research Center (BRC) also participated in one of the studies.

The two studies – Graduate 1 and Graduate 2 – did not achieve the results hoped for. In the first study, participants who received gantenerumab saw an improvement of 8% points, and in the other study they saw 6% less deterioration compared to the placebo group. These differences were not statistically significant. On November 30, Roche will share the data during the Alzheimer’s conference in San Francisco, so that we and other researchers can learn from it.

That is important, because with each study we increase our knowledge about the treatment of Alzheimer’s. Thanks in part to our participants, we are getting ever closer to a new drug, which is also getting ever closer. Currently, there are about thirty different medications for Alzheimer’s that are in the final phase of the research. We must remain positive.

Recently, there was good news about another drug, lecanemab. It seems to have a inhibitory effect on the development of the disease. Details of that will also be presented on November 29 at the same Alzheimer’s conference.

What has been investigated?

The drugs currently being studied in various trials can be classified based on their chemical class (for example, monoclonal antibody, “small molecule”, active vaccine) and based on their target site (for example, amyloid beta, tau, inflammation). Gantenerumab belongs to the class of monoclonal antibodies and targets amyloid beta. Similar drugs are lecanemab and donanemab. Although they belong to the same chemical class, they differ from each other. For example, lecanemab mainly targets soluble amyloid beta, and gantenerumab targets amyloid beta accumulated in plaques. Donanemab targets a specific extra toxic type of amyloid beta: pyroglutamate amyloid beta.

After studying the initial data, I draw a number of preliminary conclusions. The specific drug, gantenerumab, is insufficiently able to inhibit the disease process in patients with an early stage of Alzheimer's disease. The results of lecanemab, another monoclonal antibody that also targets amyloid beta, show that it is possible to slow down clinical deterioration in patients in an early stage of Alzheimer's disease. This could indicate that it is important to clear away the soluble forms of amyloid beta.

We remain resilient. The road is long, but our mission to help the world fight Alzheimer’s disease remains unchanged.